GlassScriptPhysician profile
Maryanne Speiser
NPI 1619207313
$3,822.81
in general payments reported to CMS, 2019-2025
28 companies · $832 in 2025
The $832 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $760 · 2023: $932 · 2024: $1,028 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.56 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $618.94 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $513.76 | 2022-2025 | Farxiga, Wainua, Lokelma |
| Boston Scientific Corporation | $233.47 | 2021-2025 | Watchman Access System, Varithena Administration Pack |
| Kiniksa Pharmaceuticals International, Plc | $177.62 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $176.25 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $168.21 | 2022-2025 | |
| Penumbra, INC. | $160.34 | 2025 | Ruby Coil |
| Sanofi-Aventis U.S. LLC | $133.12 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $121.86 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $89.29 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $88.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $82.52 | 2025 | |
| W. L. Gore & Associates, INC. | $80.41 | 2022 | |
| Daiichi Sankyo INC. | $77.19 | 2022-2025 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.34 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $42.33 | 2022 | |
| Philips North America LLC | $32.69 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $27.09 | 2022 | |
| Impulse Dynamics (USA) INC. | $26.71 | 2024 | Optimizer |
| Edwards Lifesciences Corporation | $23.34 | 2022 | |
| Abbott Laboratories | $22.92 | 2025 | Cardiomems |
| Amgen INC. | $22.62 | 2023 | Repatha |
| Regeneron Healthcare Solutions, INC. | $21.90 | 2025 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.82 | 2022 | |
| Resmed Corp | $19.62 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $19.44 | 2025 | Eliquis |
| Esperion Therapeutics, INC. | $17.71 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryanne Speiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.